Investor Relations

Corporate Overview

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient's lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.

Why Invest in Myriad Genetics

Myriad's 9 molecular diagnostic tests provide a preeminent market position today; our 13 innovative pipeline tests will ensure Myriad's standing for the future. The Company is focused on three initiatives for long-term growth:

  1. To grow existing tests and markets;
  2. To expand internationally; and
  3. To launch new products including companion diagnostics.

While Myriad is investing in its future, the company also boasts a balanced capital approach including returning cash to shareholders.

News Releases

Apr 22, 2014
Myriad Genetics to Announce Financial Results for the Third Quarter of Fiscal Year 2014 on Tuesday, May 6, 2014

Apr 7, 2014
Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R)

View all releases »

Events & Presentations

Myriad Corporate Presentation


Upcoming Event
May 6, 2014
4:30 PM ET
Myriad Genetics Third Quarter Fiscal 2014 Financial Results Conference Call
Webcast Listen to webcast
Reminder Remind me

View all events & presentations »


Stock Quote (NASDAQ:MYGN)

Price:
39.40
Change:
+ 1.24
Open:
38.21
Previous Close:
38.16
Day High:
39.54
Day Low:
38.21
52 Week High:
42.50
52 Week Low:
20.02
Volume:
1,520,000
4:00 PM ET on Apr 22, 2014
Delayed at least 20 minutes.
Provided by eSignal.

Investor Contact

Scott Gleason
(801) 584-1143
sgleason@myriad.com

Media Contact

Ron Rogers
Corporate Communications and Media Relations
(801) 584-3065
rrogers@myriad.com